JANX — Janux Therapeutics, Inc. stock price, charts and financials

QT43Janux Therapeutics, Inc.

Janux Therapeutics, Inc. (NASDAQ: JANX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
16.21
+0.36+2.28%
OverviewShort InterestFilings
JANXQT43Janux Therapeutics, Inc.·NASDAQ
16.21+2.28%
TA
Loading chart...
Signal & projected range
Earnings big miss — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AUPH-2.45%$15.46MESO+4.71%$16.69ZBIO-0.83%$32.16GHRS-1.62%$29.78TSHA-1.51%$6.46STOK-1.22%$32.31ABCL+39.97%$9.70VRDN-3.29%$22.81
Snapshot
Index-P/E-EPS (ttm)-0.91Insider Own-Shs Outstand60.98MPerf Week4.48%
Market Cap966.60MForward P/E-EPS next Y-2.68Insider Trans-0.02%Shs Float57.09MPerf Month-5.37%
Enterprise Value959.82MPEG-EPS next Q-Inst Own-Short Float11.30%Perf Quarter9.01%
Income-99.37MP/S30.32EPS this Y-87.36%Inst Trans-Short Ratio5.76Perf Half Y30.13%
Sales31.88MP/B1.07EPS next Y-57.36%ROA-10.18%Short Interest6.45MPerf YTD14.86%
Book/sh-P/C-EPS next 5Y-ROE-10.79%52W High36.14 -55.15%Perf Year-34.45%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-15.11%52W Low12.40 30.78%Perf 3Y24.12%
Dividend Est.-EV/EBITDA-Sales past 3/5Y3.57% -Gross Margin68.91%Volatility3.23% 3.94%Perf 5Y-51.13%
Dividend TTM-EV/Sales30.11EPS Y/Y TTM28.91%Oper. Margin-450.30%ATR (14)0.62Perf 10Y-
Dividend Ex-Date-Quick Ratio16.35Sales Y/Y TTM36.36%Profit Margin-321.81%RSI (14)53.82Recom2.33
Dividend Gr. 3/5Y-Current Ratio16.35EPS Q/Q-2.63%SMA200.78%Beta2.48Target Price29.00
Payout0.00%Debt/Eq0.02Sales Q/Q-SMA505.42%Rel Volume0.60Prev Close15.85
Employees109LT Debt/Eq0.02EarningsNov 10SMA200-4.28%Avg Volume1.04MPrice16.21
IPO DateJun 11, 2021Option/ShortYes / YesEPS/Sales Surpr.29.16% -14.32%Net Debt/EBITDA0.07Volume625,343Change2.28%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-07-26ReiteratedStifel Nicolaus$38 → $35
Aug-07-26ReiteratedGuggenheimBuy$58 → $55
Jun-25-26ReiteratedTruist Financial$26
May-11-26ReiteratedEvercore ISI$23 → $22
May-08-26ReiteratedWedbushOutperform$36
Apr-20-26DowngradeBarclaysOverweight → Underweight$29 → $14
Apr-15-26DowngradeUBSBuy → Neutral$57 → $15
Jan-20-26DowngradeClear StreetBuy → Hold
Jan-16-26ReiteratedPiper SandlerOverweight$30
Dec-17-25ReiteratedBarclaysOverweight$47 → $29
Latest News
Company

Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue321011—————
Cost of Goods Sold Incl. D&A1022—————
Gross Profit2189—————
Selling, General and Administrative Excl. Other434241—————
Research and Development12512668—————
Other Operating Expense-3-2-2—————
Operating Income-143-158-99—————
Interest Expense
000—————
Unusual Expense
————————
Non-Operating Income (Expense)414430—————
Net Income Before Taxes-102-114-69—————
Income Taxes
000—————
Consolidated Net Income-102-114-69—————
Net Income From Continuing Operations-102-114-69—————
Net Income-102-114-69—————
EPS (Recurring)-1.64-1.83-1.28—————
EPS (Basic, Before Extraordinaries)-1.64-1.83-1.28—————
EPS (Diluted)-1.64-1.83-1.28—————
EBITDA-101-112-67—————
Other After Tax Adjustments
————————
Stock Option Compensation Expense
————————
Price To Earnings Ratio
————————
Price To Sales Ratio31.9285.56262.83—————
Gross Margin65.6380.0081.82—————
Operating Margin-446.88-1,580.00-900.00—————
Net Margin-318.75-1,140.00-627.27—————
Shares Outstanding636254—————
Market Capitalization1,0218562,891—————
Operating Lease Expense
————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$38.12$30.79$23.46$16.13$8.80● Close Price0.00K125.25K250.49K375.74K500.99KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Campbell David AlanPresident and CEOJul 08 '26Option Exercise4.217,00029,470388,582Jul 10
Doyle Janeen NoelChief Corp. & Bus. Dev. OfcrJun 02 '26Sale14.034,05956,94475,941Jun 04
Dobek MariaVice President, AccountingMay 11 '26Sale14.172,03828,87832,270May 13
Meyer Andrew HollmanChief Business OfficerJan 02 '26Sale13.731,87925,79983,095Jan 02
DiRaimondo ThomasChief Scientific OfficerJan 02 '26Sale13.732,50534,394124,425Jan 02
Campbell David AlanPresident and CEOJan 02 '26Sale13.738,072110,829284,982Jan 02
Winter Charles M.Chief Technical OfficerJan 02 '26Sale13.732,40132,96677,721Jan 02
McIver ZachariahChief Medical OfficerJan 02 '26Sale13.732,71437,26323,286Jan 02
Dobek MariaVice President, AccountingJan 02 '26Sale13.731,46220,07315,373Jan 02
Meyer Andrew HollmanChief Business OfficerDec 01 '25Option Exercise10.593,33335,29688,307Dec 03
Meyer Andrew HollmanChief Business OfficerDec 01 '25Sale32.983,333109,92984,974Dec 03
Meyer Andrew HollmanChief Business OfficerNov 14 '25Option Exercise10.593,33335,29688,307Nov 14
Meyer Andrew HollmanChief Business OfficerNov 14 '25Sale30.003,33399,99084,974Nov 14
Meyer Andrew HollmanChief Business OfficerOct 28 '25Option Exercise6.7616,665112,68998,804Oct 30
Meyer Andrew HollmanChief Business OfficerOct 28 '25Sale30.0616,665500,98782,139Oct 30
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.